Research ArticleArticle
Symptoms Related to Tumor Necrosis Factor Receptor 1-associated Periodic Syndrome, Multiple Sclerosis, and Severe Rheumatoid Arthritis in Patients Carrying the TNF Receptor Superfamily 1A D12E/p.Asp41Glu Mutation
Joachim Havla, Peter Lohse, Lisa Ann Gerdes, Reinhard Hohlfeld and Tania Kümpfel
The Journal of Rheumatology January 2013, jrheum.120729; DOI: https://doi.org/10.3899/jrheum.120729
Joachim Havla
From the Institute of Clinical Neuroimmunology and the Department of Clinical Chemistry, Ludwig-Maximilians University, Munich, Germany. Dr. Hohlfeld is supported by the Deutsche Forschungsgemeinschaft (SFB 571) and has received personal compensation from Bayer-Schering Pharmacy, TEVA, Merck-Serono, Biogen-Idec, and Novartis. Dr. Havla and Dr. Gerdes have received travel expenses and personal compensation from Merck-Serono, TEVA, Bayer-Schering, Novartis, and Biogen-Idec. Dr. Kumpfel has received travel expenses and personal compensation from Bayer-Schering Pharmacy, TEVA, Merck-Serono, and Biogen-Idec as well as grant support from Bayer-Schering AG. J. Havla, MD, Institute of Clinical Neuroimmunology, Ludwig-Maximilians University; P. Lohse, MD, Department of Clinical Chemistry, Ludwig-Maximilians University, currently at the Institut of Laboratory Medicine and Human Genetics, Singen, Germany; L.A. Gerdes, MD; R. Hohlfeld, MD; T. Kumpfel, MD, Institute of Clinical Neuroimmunology, Ludwig-Maximilians University. Address correspondence to Dr. T. Kumpfel, Institute of Clinical Neuroimmunology, Campus Grosshadern Ludwig-Maximilians University, Marchioninistr. 15, D-81377 Munich, Germany. E-mail: tania.kuempfel@med.uni-muenchen.de Accepted for publication November 27, 2012.
Peter Lohse
From the Institute of Clinical Neuroimmunology and the Department of Clinical Chemistry, Ludwig-Maximilians University, Munich, Germany. Dr. Hohlfeld is supported by the Deutsche Forschungsgemeinschaft (SFB 571) and has received personal compensation from Bayer-Schering Pharmacy, TEVA, Merck-Serono, Biogen-Idec, and Novartis. Dr. Havla and Dr. Gerdes have received travel expenses and personal compensation from Merck-Serono, TEVA, Bayer-Schering, Novartis, and Biogen-Idec. Dr. Kumpfel has received travel expenses and personal compensation from Bayer-Schering Pharmacy, TEVA, Merck-Serono, and Biogen-Idec as well as grant support from Bayer-Schering AG. J. Havla, MD, Institute of Clinical Neuroimmunology, Ludwig-Maximilians University; P. Lohse, MD, Department of Clinical Chemistry, Ludwig-Maximilians University, currently at the Institut of Laboratory Medicine and Human Genetics, Singen, Germany; L.A. Gerdes, MD; R. Hohlfeld, MD; T. Kumpfel, MD, Institute of Clinical Neuroimmunology, Ludwig-Maximilians University. Address correspondence to Dr. T. Kumpfel, Institute of Clinical Neuroimmunology, Campus Grosshadern Ludwig-Maximilians University, Marchioninistr. 15, D-81377 Munich, Germany. E-mail: tania.kuempfel@med.uni-muenchen.de Accepted for publication November 27, 2012.
Lisa Ann Gerdes
From the Institute of Clinical Neuroimmunology and the Department of Clinical Chemistry, Ludwig-Maximilians University, Munich, Germany. Dr. Hohlfeld is supported by the Deutsche Forschungsgemeinschaft (SFB 571) and has received personal compensation from Bayer-Schering Pharmacy, TEVA, Merck-Serono, Biogen-Idec, and Novartis. Dr. Havla and Dr. Gerdes have received travel expenses and personal compensation from Merck-Serono, TEVA, Bayer-Schering, Novartis, and Biogen-Idec. Dr. Kumpfel has received travel expenses and personal compensation from Bayer-Schering Pharmacy, TEVA, Merck-Serono, and Biogen-Idec as well as grant support from Bayer-Schering AG. J. Havla, MD, Institute of Clinical Neuroimmunology, Ludwig-Maximilians University; P. Lohse, MD, Department of Clinical Chemistry, Ludwig-Maximilians University, currently at the Institut of Laboratory Medicine and Human Genetics, Singen, Germany; L.A. Gerdes, MD; R. Hohlfeld, MD; T. Kumpfel, MD, Institute of Clinical Neuroimmunology, Ludwig-Maximilians University. Address correspondence to Dr. T. Kumpfel, Institute of Clinical Neuroimmunology, Campus Grosshadern Ludwig-Maximilians University, Marchioninistr. 15, D-81377 Munich, Germany. E-mail: tania.kuempfel@med.uni-muenchen.de Accepted for publication November 27, 2012.
Reinhard Hohlfeld
From the Institute of Clinical Neuroimmunology and the Department of Clinical Chemistry, Ludwig-Maximilians University, Munich, Germany. Dr. Hohlfeld is supported by the Deutsche Forschungsgemeinschaft (SFB 571) and has received personal compensation from Bayer-Schering Pharmacy, TEVA, Merck-Serono, Biogen-Idec, and Novartis. Dr. Havla and Dr. Gerdes have received travel expenses and personal compensation from Merck-Serono, TEVA, Bayer-Schering, Novartis, and Biogen-Idec. Dr. Kumpfel has received travel expenses and personal compensation from Bayer-Schering Pharmacy, TEVA, Merck-Serono, and Biogen-Idec as well as grant support from Bayer-Schering AG. J. Havla, MD, Institute of Clinical Neuroimmunology, Ludwig-Maximilians University; P. Lohse, MD, Department of Clinical Chemistry, Ludwig-Maximilians University, currently at the Institut of Laboratory Medicine and Human Genetics, Singen, Germany; L.A. Gerdes, MD; R. Hohlfeld, MD; T. Kumpfel, MD, Institute of Clinical Neuroimmunology, Ludwig-Maximilians University. Address correspondence to Dr. T. Kumpfel, Institute of Clinical Neuroimmunology, Campus Grosshadern Ludwig-Maximilians University, Marchioninistr. 15, D-81377 Munich, Germany. E-mail: tania.kuempfel@med.uni-muenchen.de Accepted for publication November 27, 2012.
Tania Kümpfel
From the Institute of Clinical Neuroimmunology and the Department of Clinical Chemistry, Ludwig-Maximilians University, Munich, Germany. Dr. Hohlfeld is supported by the Deutsche Forschungsgemeinschaft (SFB 571) and has received personal compensation from Bayer-Schering Pharmacy, TEVA, Merck-Serono, Biogen-Idec, and Novartis. Dr. Havla and Dr. Gerdes have received travel expenses and personal compensation from Merck-Serono, TEVA, Bayer-Schering, Novartis, and Biogen-Idec. Dr. Kumpfel has received travel expenses and personal compensation from Bayer-Schering Pharmacy, TEVA, Merck-Serono, and Biogen-Idec as well as grant support from Bayer-Schering AG. J. Havla, MD, Institute of Clinical Neuroimmunology, Ludwig-Maximilians University; P. Lohse, MD, Department of Clinical Chemistry, Ludwig-Maximilians University, currently at the Institut of Laboratory Medicine and Human Genetics, Singen, Germany; L.A. Gerdes, MD; R. Hohlfeld, MD; T. Kumpfel, MD, Institute of Clinical Neuroimmunology, Ludwig-Maximilians University. Address correspondence to Dr. T. Kumpfel, Institute of Clinical Neuroimmunology, Campus Grosshadern Ludwig-Maximilians University, Marchioninistr. 15, D-81377 Munich, Germany. E-mail: tania.kuempfel@med.uni-muenchen.de Accepted for publication November 27, 2012.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Symptoms Related to Tumor Necrosis Factor Receptor 1-associated Periodic Syndrome, Multiple Sclerosis, and Severe Rheumatoid Arthritis in Patients Carrying the TNF Receptor Superfamily 1A D12E/p.Asp41Glu Mutation
Joachim Havla, Peter Lohse, Lisa Ann Gerdes, Reinhard Hohlfeld, Tania Kümpfel
The Journal of Rheumatology Jan 2013, jrheum.120729; DOI: 10.3899/jrheum.120729
Symptoms Related to Tumor Necrosis Factor Receptor 1-associated Periodic Syndrome, Multiple Sclerosis, and Severe Rheumatoid Arthritis in Patients Carrying the TNF Receptor Superfamily 1A D12E/p.Asp41Glu Mutation
Joachim Havla, Peter Lohse, Lisa Ann Gerdes, Reinhard Hohlfeld, Tania Kümpfel
The Journal of Rheumatology Jan 2013, jrheum.120729; DOI: 10.3899/jrheum.120729